Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 18/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021685 | 1.00 | GRM5 (0.45) | GRM5MEN1RAB9AKMT2APGR | |
| SCHEMBL10279583 | 0.87 | GRM5 (0.54) | GRM5MEN1RAB9AKMT2APGR | |
| SCHEMBL10279582 | 0.87 | GRM5 (0.54) | GRM5MEN1RAB9AKMT2APGR | |
| SCHEMBL5021544 | 0.87 | GRM5 (0.52) | GRM5MEN1RAB9AKMT2A | |
| SCHEMBL5021546 | 0.87 | GRM5 (0.52) | GRM5MEN1RAB9AKMT2A | |
| SCHEMBL16364184 | 0.83 | GRM5 (0.58) | GRM5 | |
| SCHEMBL10279529 | 0.83 | GRM5 (0.49) | GRM5MEN1RAB9AKMT2APGR | |
| SCHEMBL10279528 | 0.83 | GRM5 (0.49) | GRM5MEN1RAB9AKMT2APGR | |
| SCHEMBL5021742 | 0.83 | GRM5 (0.54) | GRM5MEN1RAB9AKMT2A | |
| SCHEMBL13642150 | 0.83 | GRM5 (0.54) | GRM5MEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
| WO-2012064603-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | GRM5, GRIK5, GRM1 | GRM5 1/4885MEN1 4226/4885RAB9A 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.